Research on the varieties, characteristics of new anti-HBV drugs and related clinical trials / 中华临床感染病杂志

ABSTRACT

HBV infection is a major public health threat around the world.At present, clinical anti-HBV drugs,including nucleoside/nucleotide analogues (NAs) and PegIFNα, can only directly or indirectly inhibit viral replication rather than viral elimination.In recent years, medical researchers and pharmaceutical enterprises are extensively researching and developing new drugs for treatment of HBV, and a variety of drugs have entered the stage of clinical trials.This article reviews the research progress on characteristics,safety and clinical trials,as well as the development trends of several currently available anti-HBV drugs, focusing on the target points and life cycle of HBV.